A Study of NB003 in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-07-06
Target enrollment:
Participant gender:
Summary
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and
Pharmacokinetics of NB004 in Subjects with Advanced Solid Tumors